LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.

MLA

Zhang, Xin, et al. “LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.” Clinical Pharmacology in Drug Development, vol. 6, no. 6, Nov. 2017, pp. 556–63. EBSCOhost, https://doi.org/10.1002/cpdd.392.

APA

Zhang, X., Lam, E. C. Q., Seger, M. E., Coutant, D., Chua, L., Tan, L. H., Soon, D., & Linnebjerg, H. (2017). LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels. Clinical Pharmacology in Drug Development, 6(6), 556–563. https://doi.org/10.1002/cpdd.392

Chicago

Zhang, Xin, Eric Chen Quin Lam, Mary E Seger, David Coutant, Laiyi Chua, Lai Hock Tan, Danny Soon, and Helle Linnebjerg. 2017. “LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.” Clinical Pharmacology in Drug Development 6 (6): 556–63. doi:10.1002/cpdd.392.